NOV 11, 2016 5:21 AM PST

Rethinking the Benefits vs. Cost of Expensive New Cancer Drugs

WRITTEN BY: Xuan Pham
Unlike most fields of biology and science that’s suffering from lack of funding, cancer research is a booming business. Mark Zuckerberg, founder of Facebook, recently announced a $3 billion initiative to cure human diseases – chief among them is cancer. Sean Parker, cofounder of Napster, committed $250 million to developing new cancer treatments. And a coalition of philanthropists led by Michael Bloomberg is adding another $100 million to the cancer research pot.
 

But despite huge financial investments in cancer research, some studies find that new cancer drugs approved in the last decade have only improved survival marginally. This poses serious ethical concerns for Peter Wise, a bioethicist who voiced his opinions in a BMJ article.
 
For Wise, expensive new drugs that prolong survival by one or two months does not quite justify the increasing cancer costs to the patient and the healthcare system. And perhaps, at the end of the day, it’s the pharmaceutical companies that make the biggest profit with these new drugs, not the patients. Indeed, in 2015 alone, global sales of cancer drugs topped $150 billion dollars.
 
"The approval of drugs with such small survival benefits raises ethical questions, including whether recipients are aware of the drugs' limited benefits, whether the high cost to benefit ratios are justified, and whether trials are providing the right information," Wise wrote.
 


Importantly, the article is not a complete dismissal of the value of cancer research. Wise noted that the five-year survival mark has increased from 49 percent to 68 percent in the past four decades. This jump in survival surely would not have been possible without the treatment advances in this time.
 
But Wise argues that the improvement in cancer survival may not all be due to new drugs. Other factors, such as better education, changing lifestyles, improved screening and prevention measures may have also contributed to the fight against cancer.
 
Wise also brings up potential patient misinformation with every new cancer drug. Yes, new drugs bring hope and excitement to cancer patients, but Wise cautions against leading patients to have unrealistic expectations with new drugs.

"Good cancer care demands empowerment of patients with accurate, impartial information followed by genuinely informed consent in both the clinical trial and therapeutic settings," Wise wrote. "Ethical impediments to sound practice need to be addressed and corrected."

"Above all, the threshold for approval of new and existing cancer drugs needs to be raised - using more meaningful disease specific criteria of risk-benefit and cost-benefit," he concluded.
 
Additional sources: MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 24, 2019
Drug Discovery & Development
NOV 24, 2019
The Fight Against Lethal Childhood Brain Cancers
Scientists used studies on cell and animal models to reveal insights into lethal childhood brain cancers and find promising drug therapeutics. The deadly c...
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
Making T-Cell Therapy Even More Effective
Curated w/video - CRISPR/Cas9 deletion of an enzyme resulted in longer lasting, more robust therapy....
JAN 17, 2020
Cancer
JAN 17, 2020
Could salt nanoparticles kill cancer?
Could salt be the key to killing cancer cells? A new study published in Advanced Materials reports success in using sodium chloride to destroy cancer cells...
FEB 02, 2020
Cell & Molecular Biology
FEB 02, 2020
New T Cell Therapy is a Universal Approach to Target Cancer
For years, researchers have been trying to harness the power of the assassins of the immune system - killer T cells....
FEB 10, 2020
Immunology
FEB 10, 2020
How Cancer Evades the Immune System Time and Time Again
Scientists discovered a new mechanism by which cancer cells evade the immune system to further their own agenda: invade, multiply, and spread. Identifying...
FEB 13, 2020
Cancer
FEB 13, 2020
Can Ebola help treat glioblastomas?
You might want to sit down for this. New research published in the Journal of Virology has named a surprising new ally to brain tumors: Ebola. Yes, yo...
Loading Comments...